Ark Laboratory LLC

Ark Laboratory LLC was paid $38.53M by Medicaid between Jan 2018 and Jan 2024, across 157 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 28% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Michigan

Rank by total paid#4 of 108

Median peer was paid$588K

This provider vs. median66×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	22,801	$2.09M
2019	46,145	$3.58M
2020	132,400	$8.88M
2021	191,879	$10.55M
2022	193,491	$8.55M
2023	130,099	$4.86M
2024incomplete	818	$21K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	28%	83,325	51,920	$10.93M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	16%	90,921	73,477	$6.11M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	13%	82,305	34,444	$4.93M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	12%	46,684	29,235	$4.81M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	12%	150,530	83,486	$4.56M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	3.8%	16,566	10,345	$1.47M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	3.2%	17,602	12,449	$1.24M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.4%	49,861	40,827	$927K
87481		<1%	6,121	5,953	$357K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	1,800	1,755	$352K
87631		<1%	4,379	3,897	$287K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	2,533	2,490	$277K

145 more codes

87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	10,199	$198K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	10,042	$195K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	9,479	$154K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	1,418	$127K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	2,971	$113K
87511		<1%	5,374	$104K
87653		<1%	5,052	$92K
87634		<1%	2,705	$91K
87640		<1%	4,724	$86K
87529		<1%	2,596	$77K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	5,189	$74K
87563		<1%	3,019	$62K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,550	$60K
84443	Thyroid stimulating hormone (TSH)	<1%	6,641	$59K
87500		<1%	2,950	$49K
80053	Comprehensive metabolic panel	<1%	7,682	$44K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	351	$39K
87641		<1%	2,263	$38K
80061	Lipid panel	<1%	5,694	$38K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	9,274	$37K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,854	$35K
87503		<1%	2,748	$31K
80074		<1%	1,458	$29K
36415	Collection of venous blood by venipuncture	<1%	9,024	$25K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	1,740	$24K
83036	Hemoglobin; glycosylated (A1C)	<1%	4,929	$23K
81420	Fetal chromosomal aneuploidy genomic sequence analysis panel	<1%	53	$22K
87486		<1%	1,137	$20K
87581		<1%	1,144	$20K
82607		<1%	2,505	$20K
84439		<1%	4,077	$19K
86769		<1%	547	$19K
87541		<1%	1,058	$19K
84481		<1%	1,850	$16K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	<1%	864	$12K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	652	$12K
87086	Culture, bacterial; quantitative colony count, urine	<1%	2,181	$11K
86830		<1%	352	$11K
82746		<1%	1,382	$10K
86780		<1%	1,164	$8K
86803		<1%	944	$7K
81511		<1%	76	$7K
84425		<1%	540	$6K
82728		<1%	744	$6K
83013		<1%	225	$6K
84146		<1%	576	$5K
84403		<1%	322	$5K
87806		<1%	376	$5K
87498		<1%	298	$5K
87340		<1%	755	$5K
83735		<1%	924	$4K
87186		<1%	362	$4K
87184		<1%	601	$3K
82248		<1%	1,481	$3K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	279	$3K
87077		<1%	597	$3K
86703		<1%	470	$3K
87102		<1%	658	$3K
84702		<1%	340	$3K
85027		<1%	683	$3K
86762		<1%	293	$3K
87070		<1%	447	$2K
87088		<1%	470	$2K
86787		<1%	287	$2K
83540		<1%	620	$2K
86705		<1%	435	$2K
87501		<1%	188	$2K
86709		<1%	433	$2K
87341		<1%	456	$2K
84466		<1%	218	$2K
80164		<1%	235	$2K
86592		<1%	595	$2K
81001		<1%	1,028	$2K
86850		<1%	248	$1K
82043		<1%	525	$1K
86003		<1%	54	$1K
86038		<1%	233	$1K
87625		<1%	47	$1K
86376		<1%	155	$1K
83655		<1%	144	$1K
84480		<1%	108	$970.04
82784		<1%	133	$892.41
83001		<1%	74	$891.46
87536		<1%	15	$887.81
84153		<1%	129	$851.26
87185		<1%	386	$764.68
82785		<1%	149	$759.21
86235		<1%	42	$759.03
85651		<1%	347	$752.95
84460		<1%	227	$751.55
84450		<1%	226	$731.05
82570		<1%	342	$678.92
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	33	$666.87
86140		<1%	208	$642.98
80076		<1%	189	$569.16
84402		<1%	40	$562.80
81003		<1%	494	$554.59
80048	Basic metabolic panel (calcium, ionized)	<1%	99	$533.46
84100		<1%	211	$498.55
86900		<1%	266	$485.47
86901		<1%	266	$474.53
80184		<1%	48	$413.46
87522	Neg quan hep c or qual rna	<1%	13	$397.36
84479		<1%	876	$393.04
84550		<1%	139	$381.33
82565		<1%	117	$376.23
82550		<1%	87	$339.18
83550		<1%	230	$338.65
83690		<1%	76	$300.12
84520		<1%	122	$295.04
82947		<1%	117	$281.92
83970		<1%	12	$273.42
80051		<1%	54	$257.74
86696		<1%	16	$230.82
88142		<1%	18	$228.48
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	14	$214.12
86706		<1%	33	$211.20
80178		<1%	39	$158.42
82150		<1%	43	$157.89
86695		<1%	16	$157.26
83992		<1%	13	$145.09
83002		<1%	12	$138.05
82465		<1%	63	$136.88
84154		<1%	15	$135.61
86800		<1%	12	$129.09
83525		<1%	13	$94.52
86225		<1%	30	$93.28
81025		<1%	15	$79.06
84165		<1%	12	$61.86
87081		<1%	13	$51.60
86431		<1%	12	$43.57
80050	General health panel	<1%	12	$39.54
84295		<1%	12	$38.16
84132		<1%	12	$37.80
80069		<1%	37	$33.07
84703		<1%	12	$27.73
85007		<1%	29	$17.01
85008		<1%	97	$8.40
80354		0%	15	$0.00
80321		0%	14	$0.00
80348		0%	16	$0.00
80355		0%	139	$0.00
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	0%	64	$0.00
80349		0%	16	$0.00
80353		0%	13	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGROSSI, JAMES (OWNER)